Assembly Biosciences Inc (NASDAQ:ASMB) Stake Reduced by Alps Advisors Inc.

Alps Advisors Inc. reduced its stake in shares of Assembly Biosciences Inc (NASDAQ:ASMB) by 4.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,256 shares of the biopharmaceutical company’s stock after selling 2,219 shares during the quarter. Alps Advisors Inc.’s holdings in Assembly Biosciences were worth $504,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Bank of Montreal Can grew its stake in Assembly Biosciences by 2,084.1% during the 2nd quarter. Bank of Montreal Can now owns 1,922 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 1,834 shares during the last quarter. Rhumbline Advisers grew its stake in Assembly Biosciences by 8.3% during the 3rd quarter. Rhumbline Advisers now owns 34,939 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 2,667 shares during the last quarter. FMR LLC grew its stake in Assembly Biosciences by 0.6% during the 1st quarter. FMR LLC now owns 445,716 shares of the biopharmaceutical company’s stock worth $8,776,000 after buying an additional 2,680 shares during the last quarter. Quantamental Technologies LLC grew its stake in Assembly Biosciences by 16,941.2% during the 2nd quarter. Quantamental Technologies LLC now owns 2,897 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 2,880 shares during the last quarter. Finally, Swiss National Bank grew its stake in Assembly Biosciences by 8.1% during the 2nd quarter. Swiss National Bank now owns 42,700 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 3,200 shares during the last quarter. Hedge funds and other institutional investors own 81.21% of the company’s stock.

Several research analysts have recently issued reports on the company. ValuEngine raised Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. BidaskClub raised Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, October 17th. Robert W. Baird set a $74.00 price target on Assembly Biosciences and gave the stock a “buy” rating in a research note on Thursday, October 17th. Chardan Capital reissued a “neutral” rating on shares of Assembly Biosciences in a research note on Thursday, September 19th. Finally, Zacks Investment Research cut Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Assembly Biosciences has a consensus rating of “Buy” and an average target price of $36.40.

NASDAQ:ASMB opened at $14.03 on Thursday. Assembly Biosciences Inc has a 1 year low of $8.13 and a 1 year high of $27.60. The stock has a market cap of $444.88 million, a price-to-earnings ratio of -3.53 and a beta of 1.58. The business has a fifty day moving average of $13.00 and a 200-day moving average of $13.54. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.69 and a current ratio of 7.69.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.93) by ($0.03). Assembly Biosciences had a negative return on equity of 52.83% and a negative net margin of 647.72%. The business had revenue of $4.23 million during the quarter, compared to the consensus estimate of $3.45 million. On average, equities research analysts predict that Assembly Biosciences Inc will post -3.64 EPS for the current year.

Assembly Biosciences Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Featured Story: Why do analysts give a neutral rating?

Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.